CTOs on the Move

AnkaBehavioralHealth

www.ankabhi.org

 
All of Ankas programs share the same mission: to eliminate the impact of behavioral health problems for all people.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

Teva Canada

Teva Canada is a Scarborough, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kaup Pharmacy

Kaup Pharmacy is a Fort Recovery, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Covis Pharma

Covis Pharma is a global specialty pharmaceutical company that markets therapeutic solutions for patients with life-threatening conditions and chronic illnesses. Our paramount concern is patient`s outcomes as we focus on improving the health of people with serious medical conditions. Covis Pharma is a standalone company with global commercial, business development, product supply chain, product development, quality and regulatory functions based in Zug, Switzerland.

Sanofi

3129 Sanofi SA is a French multinational healthcare company headquartered in Paris, France.

Opko

OPKO Health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. Our diagnostics business includes BioReference Laboratories, the nation`s third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA approved treatment for SHPT in stage 3-¬4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBITM for chemotherapy induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), OPK88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in Phase 2 clinical trials, among the new class of GLP-¬1 glucagon receptor dual agonists, and OPK88003, a selective androgen receptor modulator for benign prostatic hyperplasia (Phase 2). Our biologics business includes hGH-¬CTP, a once weekly human growth hormone in Phase 3 and partnered with Pfizer; and a long-¬acting Factor VIIa drug for hemophilia in Phase 2a.